Infectious Disease · Clinical trials
COVID-19 Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About covid-19 — and why its trials are hard
COVID-19, caused by SARS-CoV-2, produces illness ranging from mild upper respiratory symptoms to severe pneumonia, thrombosis, and death, with highest risk in older and immunocompromised people. Management combines prevention through mRNA and protein-based vaccines with outpatient and inpatient therapeutics. For high-risk outpatients, oral antivirals nirmatrelvir/ritonavir (Paxlovid) and molnupiravir (Lagevrio), plus IV remdesivir (Veklury), reduce progression when started early. In hospitalized patients, remdesivir shortens recovery and immunomodulators (dexamethasone, tocilizumab, baricitinib) reduce mortality. A defining feature of the field is attrition: many once-promising therapies failed rigorous trials, and most monoclonal antibodies were deauthorized after successive variants (Omicron and descendants) escaped neutralization. Repurposed drugs such as hydroxychloroquine and lopinavir/ritonavir showed no benefit in large randomized trials. Vaccine and treatment strategies continue to be updated against evolving variants, and evidence standards from platform trials like RECOVERY and SOLIDARITY reshaped how the drugs were evaluated.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Nirmatrelvir/ritonavir (Paxlovid) | 2023 | Oral antiviral for mild-to-moderate COVID-19 in high-risk outpatients (EUA Dec 2021; full FDA approval 2023) | EPIC-HR (phase 2/3, NEJM 2022) | COVID-19-related hospitalization or death through day 28 | ~89% relative risk reduction when started within 3 days of symptom onset (~88% within 5 days) in unvaccinated high-risk adults. |
| Remdesivir (Veklury) | 2020 | IV antiviral for hospitalized and, later, high-risk outpatient COVID-19 | ACTT-1 (phase 3, NEJM 2020) | Time to clinical recovery | Shortened median recovery from 15 to ~10-11 days versus placebo in hospitalized patients; PINETREE showed ~87% reduction in hospitalization in high-risk outpatients. |
| Molnupiravir (Lagevrio) | 2021 | Oral antiviral for high-risk outpatients when alternatives are unsuitable (EUA only; not FDA-approved) | MOVe-OUT (phase 3, NEJM 2022) | COVID-19-related hospitalization or death through day 29 | ~30% relative risk reduction in the final analysis (lower than the interim ~50%), contributing to its more limited role. |
| BNT162b2 mRNA vaccine (Comirnaty) | 2021 | mRNA vaccine for prevention of COVID-19 (EUA Dec 2020; full approval Aug 2021) | C4591001 (phase 3, NEJM 2020) | Efficacy against symptomatic laboratory-confirmed COVID-19 | ~95% efficacy against symptomatic COVID-19 in the original trial (pre-Omicron era). |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in covid-19 development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Hydroxychloroquine — RECOVERY and SOLIDARITY (large randomized trials, 2020) | No reduction in mortality or clinical benefit in hospitalized COVID-19; use abandoned | Lack of in vivo antiviral efficacy at achievable doses; early enthusiasm rested on small, uncontrolled observational data. |
| Anti-spike monoclonal antibodies (e.g., bamlanivimab, casirivimab/imdevimab, sotrovimab, bebtelovimab) — Original RCTs positive, but real-world activity lost as variants emerged | Deauthorized/withdrawn as Omicron and subvariants escaped neutralization | Spike protein mutations abolished antibody binding; static antibodies could not keep pace with viral evolution. |
| Lopinavir/ritonavir — RECOVERY and SOLIDARITY (2020) | No mortality or clinical benefit in hospitalized COVID-19 | Insufficient antiviral potency against SARS-CoV-2 at tolerated exposures. |
Choosing the right endpoint
Primary endpoints that matter in covid-19 trials
- COVID-19-related hospitalization or death — Primary endpoint for outpatient antivirals in high-risk populations (e.g., EPIC-HR, MOVe-OUT).
- Time to clinical recovery — Primary endpoint in hospitalized trials such as ACTT-1 for remdesivir.
- All-cause mortality — Definitive hospitalized-patient endpoint used by platform trials (RECOVERY, SOLIDARITY).
- Efficacy against symptomatic laboratory-confirmed COVID-19 — Primary vaccine endpoint; measured efficacy declines against immune-escape variants.
How iNGENū runs covid-19 trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
COVID-19 clinical trials — FAQs
When should Paxlovid be taken?
Why did the COVID monoclonal antibodies stop being used?
Did hydroxychloroquine work for COVID-19?
Ready to discuss your covid-19 trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal